To include your compound in the COVID-19 Resource Center, submit it here.

VX-175 (GW433908): Began Phase III studies

A separate 48-week international trial of >600 treatment-naive patients will compare 3 VX-175 tablets given

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE